Barnes Jewish Hospital, St. Louis, Missouri, USA.
Anesthesiology. 2011 Dec;115(6):1349-62. doi: 10.1097/ALN.0b013e31823422e8.
Anesthesiologists are increasingly confronting the difficult problem of caring for patients with sepsis in the operating room and in the intensive care unit. Sepsis occurs in more than 750,000 patients in the United States annually and is responsible for more than 210,000 deaths. Approximately 40% of all intensive care unit patients have sepsis on admission to the intensive care unit or experience sepsis during their stay in the intensive care unit. There have been significant advances in the understanding of the pathophysiology of the disorder and its treatment. Although deaths attributable to sepsis remain stubbornly high, new treatment algorithms have led to a reduction in overall mortality. Thus, it is important for anesthesiologists and critical care practitioners to be aware of these new therapeutic regimens. The goal of this review is to include practical points on important advances in the treatment of sepsis and provide a vision of future immunotherapeutic approaches.
麻醉师在手术室和重症监护病房中越来越多地面临治疗脓毒症患者的难题。在美国，每年有超过 75 万名患者发生脓毒症，导致超过 21 万人死亡。大约 40%的重症监护病房患者在入住重症监护病房时患有脓毒症，或在重症监护病房期间发生脓毒症。人们对该疾病的病理生理学及其治疗方法有了重大的认识进展。尽管与脓毒症相关的死亡人数仍然居高不下，但新的治疗方案已导致总体死亡率降低。因此，麻醉师和重症监护医生了解这些新的治疗方案非常重要。本综述的目的是纳入脓毒症治疗方面重要进展的实用要点，并展望未来的免疫治疗方法。
